The U.S. asthma market has become increasingly crowded with a large number of approved therapies. Those include several LABA/ICSFDCs (i.e., GlaxoSmithKline’s Advair and Breo, AstraZeneca’s Symbicort, Merck & Co.’s Dulera, and Teva Pharmaceutical’s AirDuo and its authorized generic), numerous ICSs (e.g., GSK’s Flovent, Teva’s Qvar), a number of SABAs (e.g., Teva’s ProAir, GSK’s Ventolin), montelukast (Merck’s Singulair), Boehringer Ingelheim’s Spiriva, and biologics (Roche’s Xolair, GSK’s Nucala, Teva’s Cinqair, and AstraZeneca’s Fasenra), among others. The market is expected to become even more competitive in the next few years, with upcoming approvals of additional biological agents and triple LABA/LAMA/ICS combinations, making brand differentiation and understanding of key patient characteristics ever more critical for marketers.
- What are the demographic characteristics and clinical profiles of asthma patients receiving maintenance treatment with ICSs, LABA/ICSFDCs, LAMAs, SABAs, and biologics?
- What are the key risk factors, comorbidities, and coprescribed therapies by patient segment for asthma?
- How do patient cohorts for asthma compare in care utilization and outcomes (physician visits and other healthcare encounters)?
- What insurance type do asthma patients have?
- What are the reimbursed and out-of-pocket costs?
- What provider specialties are associated with asthma patient claims?
Patient Profiler provides disease-specific, patient-level analysis of the key demographic, clinical, and cost-based metrics underlying brand use, all sourced with DRG’s comprehensive real-world data (RWD) repository.
Markets covered: United States
Real-World data: U.S. electronic health records and claims data
Key drugs covered: Advair, Symbicort, Dulera, Breo, AirDuo, salmeterol/fluticasone generic, Xolair, Nucala, Spiriva, Incruse, Qvar, Flovent, ProAir, Ventolin, and others
Key analysis provided:
- Patient demographics.
- Disease-Specific lab tests and values.
- Risk factors and comorbidities.
- Coprescribing and adjunct therapy prescribing for comorbid conditions.
- Insurance type and reimbursement/cost analysis.
- Utilization of care and physician and prescriber demographics.
- Asthma - Current Treatment - Detailed, Expanded Analysis: Patient Profiler (US)
- Patient Profiler - Asthma [May 2018]
- Please Note:
Elena Kozhemyakina, Ph.D.
Elena Kozhemyakina, Ph.D., is a director on the Immune and Inflammatory Disorders team at Clarivate. She manages a team of analysts generating syndicated market research products on asthma, COPD, systemic lupus erythematosus, and urticaria. Previously, Dr. Kozhemyakina completed a postdoctoral fellowship at Harvard Medical School, where she investigated molecular mechanisms involved in limb patterning, cartilage formation, and pathogenesis of osteoarthritis. She has authored multiple peer-reviewed publications on molecular signaling in developmental disorders. She received her Ph.D. from the West Virginia University School of Medicine.